Proteonomix, Inc. PROT

PROT Company Overview

Proteonomix, Inc. (OTC: PROT) is a U.S.-based biotechnology company historically focused on regenerative medicine, stem cell therapeutics, and biomedical research commercialization. Public disclosures and historical market filings describe the company as operating in the broader biotechnology and life sciences sector, with an emphasis on adult stem cell technologies, cellular therapies, and related intellectual property development. The company has also been associated with therapeutic research initiatives targeting cardiovascular disease, wound healing, and tissue regeneration applications.

Historically, the company’s business model centered on developing and licensing stem cell-related technologies, pursuing collaborative research relationships, and advancing regenerative medicine concepts toward commercialization. Publicly available information indicates that Proteonomix sought to differentiate itself through ownership or control of proprietary stem cell processing techniques and biomedical patents. However, recent independently verifiable operational disclosures are limited, and current large-scale commercial activity, revenue generation, and active product commercialization remain unclear based on available public sources.